152 related articles for article (PubMed ID: 21222624)
1. Interaction of prolyl oligopeptidase with α-synuclein.
Lambeir AM
CNS Neurol Disord Drug Targets; 2011 May; 10(3):349-54. PubMed ID: 21222624
[TBL] [Abstract][Full Text] [Related]
2. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein.
Brandt I; Gérard M; Sergeant K; Devreese B; Baekelandt V; Augustyns K; Scharpé S; Engelborghs Y; Lambeir AM
Peptides; 2008 Sep; 29(9):1472-8. PubMed ID: 18571285
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
4. Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction.
Savolainen MH; Yan X; Myöhänen TT; Huttunen HJ
J Biol Chem; 2015 Feb; 290(8):5117-5126. PubMed ID: 25555914
[TBL] [Abstract][Full Text] [Related]
5. The role of phosphorylation in synucleinopathies: focus on Parkinson's disease.
Cavallarin N; Vicario M; Negro A
CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):471-81. PubMed ID: 20522010
[TBL] [Abstract][Full Text] [Related]
6. Inhibition-mediated changes in prolyl oligopeptidase dynamics possibly related to α-synuclein aggregation.
Walczewska-Szewc K; Rydzewski J; Lewkowicz A
Phys Chem Chem Phys; 2022 Feb; 24(7):4366-4373. PubMed ID: 35112120
[TBL] [Abstract][Full Text] [Related]
7. Synucleins in synaptic plasticity and neurodegenerative disorders.
Clayton DF; George JM
J Neurosci Res; 1999 Oct; 58(1):120-9. PubMed ID: 10491577
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons.
McLean PJ; Kawamata H; Hyman BT
Neuroscience; 2001; 104(3):901-12. PubMed ID: 11440819
[TBL] [Abstract][Full Text] [Related]
9. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
Spillantini MG; Goedert M
Ann N Y Acad Sci; 2000; 920():16-27. PubMed ID: 11193145
[TBL] [Abstract][Full Text] [Related]
10. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
[TBL] [Abstract][Full Text] [Related]
11. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
Goedert M
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
[TBL] [Abstract][Full Text] [Related]
12. Cell Biology and Pathophysiology of α-Synuclein.
Burré J; Sharma M; Südhof TC
Cold Spring Harb Perspect Med; 2018 Mar; 8(3):. PubMed ID: 28108534
[TBL] [Abstract][Full Text] [Related]
13. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein.
Kahle PJ; Neumann M; Ozmen L; Haass C
Ann N Y Acad Sci; 2000; 920():33-41. PubMed ID: 11193173
[TBL] [Abstract][Full Text] [Related]
14. Synphilin-1A: an aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients.
Eyal A; Szargel R; Avraham E; Liani E; Haskin J; Rott R; Engelender S
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5917-22. PubMed ID: 16595633
[TBL] [Abstract][Full Text] [Related]
15. New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro.
Kumar R; Bavi R; Jo MG; Arulalapperumal V; Baek A; Rampogu S; Kim MO; Lee KW
Sci Rep; 2017 Sep; 7(1):10827. PubMed ID: 28883518
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.
Dokleja L; Hannula MJ; Myöhänen TT
Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592
[TBL] [Abstract][Full Text] [Related]
17. Prolyl oligopeptidase: a rising star on the stage of neuroinflammation research.
Penttinen A; Tenorio-Laranga J; Siikanen A; Morawski M; Rossner S; García-Horsman JA
CNS Neurol Disord Drug Targets; 2011 May; 10(3):340-8. PubMed ID: 21222623
[TBL] [Abstract][Full Text] [Related]
18. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.
Myöhänen TT; Norrbacka S; Savolainen MH
Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease and other alpha-synucleinopathies.
Goedert M
Clin Chem Lab Med; 2001 Apr; 39(4):308-12. PubMed ID: 11388653
[TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein and Parkinson's disease.
Golbe LI
Mov Disord; 1999 Jan; 14(1):6-9. PubMed ID: 9918338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
